|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bonifácio VDB: Ovarian cancer biomarkers:
Moving forward in early detection. Adv Exp Med Biol. 1219:355–363.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
6
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Visone R and Croce CM: miRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li M, Wang J and Liu H: Downregulation of
miR-638 promotes progression of breast cancer and is associated
with prognosis of breast cancer patients. Onco Targets Ther.
11:6871–6877. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shen Y, Chen H, Gao L, Zhang W, He J, Yang
X, Qin L, Xue X and Guo Z: miR-638 acts as a tumor suppressor gene
in gastric cancer. Oncotarget. 8:108170–108180. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wei H, Zhang JJ and Tang QL: miR-638
inhibits cervical cancer metastasis through Wnt/β-catenin signaling
pathway and correlates with prognosis of cervical cancer patients.
Eur Rev Med Pharmacol Sci. 21:5587–5593. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bhattacharya A, Schmitz U, Raatz Y,
Schönherr M, Kottek T, Schauer M, Franz S, Saalbach A, Anderegg U,
Wolkenhauer O, et al: miR-638 promotes melanoma metastasis and
protects melanoma cells from apoptosis and autophagy. Oncotarget.
6:2966–2980. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ren Y, Chen Y, Liang X, Lu Y, Pan W and
Yang M: miRNA-638 promotes autophagy and malignant phenotypes of
cancer cells via directly suppressing DACT3. Cancer Lett.
390:126–136. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lu X, Chen L, Chen Y, Shao Q and Qin W:
Bafilomycin A1 inhibits the growth and metastatic potential of the
BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and
induces alterations in their microRNA expression. Exp Ther Med.
10:1829–1834. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Penzo C, Arnoldo L, Pegoraro S, Petrosino
S, Ros G, Zanin R, Wiśniewski JR, Manfioletti G and Sgarra R: HMGA1
modulates gene transcription sustaining a tumor signalling pathway
acting on the epigenetic status of triple-negative breast cancer
cells. Cancers (Basel). 11(1105)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang Y, Hu L, Zheng Y and Guo L: HMGA1 in
cancer: Cancer classification by location. J Cell Mol Med.
23:2293–2302. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lund T, Holtlund J, Fredriksen M and
Laland SG: On the presence of two new high mobility group-like
proteins in HeLa S3 cells. FEBS Lett. 152:163–167. 1983.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Méndez O, Pérez J, Soberino J, Racca F,
Cortés J and Villanueva J: Clinical implications of extracellular
HMGA1 in breast cancer. Int J Mol Sci. 20(5950)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zanin R, Pegoraro S, Ros G, Ciani Y,
Piazza S, Bossi F, Bulla R, Zennaro C, Tonon F, Lazarevic D, et al:
HMGA1 promotes breast cancer angiogenesis supporting the stability,
nuclear localization and transcriptional activity of FOXM1. J Exp
Clin Cancer Res. 38(313)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cao XP, Cao Y, Zhao H, Yin J and Hou P:
HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes
by regulating c-myc expression. Biochem Biophys Res Commun.
516:457–465. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jing Z, Liu C, Zhang QH, Chen L, Shen YY,
Chen YJ, Zeng X, Zu XY and Cao RX: TGF-β1 induces HMGA1 expression:
The role of HMGA1 in thyroid cancer proliferation and invasion. Int
J Oncol. 50:1567–1578. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Peters DG, Kudla DM, DeLoia JA, Chu TJ,
Fairfull L, Edwards RP and Ferrell RE: Comparative gene expression
analysis of ovarian carcinoma and normal ovarian epithelium by
serial analysis of gene expression. Cancer Epidemiol Biomarkers
Prev. 14:1717–1723. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu Y, Wang Y, Zhang Y, Fu J and Zhang G:
Knockdown of HMGA1 expression by short/small hairpin RNA inhibits
growth of ovarian carcinoma cells. Biotechnol Appl Biochem. 59:1–5.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Ma T, Zhao Z, Wang Z, Wang C and Zhang L:
miR-940 inhibits migration and invasion of tongue squamous cell
carcinoma via regulatingCXCR2/NF-κB system-mediated
epithelial-mesenchymal transition. Naunyn Schmiedebergs Arch
Pharmacol. 392:1359–1369. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schmittgen TD and Livak KJ: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
González-Magaña A and Blanco FJ: Human
PCNA structure, function and interactions. Biomolecules.
10(570)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Heneghan HM, Miller N and Kerin MJ: miRNAs
as biomarkers and therapeutic targets in cancer. Curr Opin
Pharmacol. 10:543–550. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen
H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2
to inhibit the malignancy of ovarian cancer cells. Arch Biochem
Biophys. 661:1–9. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Creighton CJ, Fountain MD, Yu Z, Nagaraja
AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM and
Anderson ML: Molecular profiling uncovers a p53-associated role for
microRNA-31 in inhibiting the proliferation of serous ovarian
carcinomas and other cancers. Cancer Res. 70:1906–1915.
2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chao A, Lin CY, Lee YS, Tsai CL, Wei PC,
Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of
ovarian cancer progression by microRNA-187 through targeting
Disabled homolog-2. Oncogene. 31:764–775. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao W, Han T, Li B, Ma Q, Yang P and Li
H: miR-552 promotes ovarian cancer progression by regulating PTEN
pathway. J Ovarian Res. 12(121)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev. 9:287–314. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhao LY, Yao Y, Han J, Yang J, Wang XF,
Tong DD, Song TS, Huang C and Shao Y: miR-638 suppresses cell
proliferation in gastric cancer by targeting Sp2. Dig Dis Sci.
59:1743–1753. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cheng J, Chen Y, Zhao P, Liu X, Dong J, Li
J, Huang C, Wu R and Lv Y: Downregulation of miRNA-638 promotes
angiogenesis and growth of hepatocellular carcinoma by targeting
VEGF. Oncotarget. 7:30702–30711. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Juríková M, Danihel L', Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 118:544–552.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhao H, Ho PC, Lo YH, Espejo A, Bedford
MT, Hung MC and Wang SC: Interaction of proliferation cell nuclear
antigen (PCNA) with c-Abl in cell proliferation and response to DNA
damages in breast cancer. PLoS One. 7(e29416)2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Madhumati G, Kavita S, Anju M, Uma S and
Raj M: Immunohistochemical expression of cell proliferating nuclear
antigen (PCNA) and p53 protein in cervical cancer. J Obstet Gynecol
India. 62:557–561. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer.
14(57)2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Khan S, Brougham CL, Ryan J, Sahrudin A,
O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM:
miR-379 regulates Cyclin B1 expression and is decreased in breast
cancer. PLoS One. 8(e68753)2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Radu A, Neubauer V, Akagi T, Hanafusa H
and Georgescu MM: PTEN induces cell cycle arrest by decreasing the
level and nuclear localization of cyclin D1. Mol Cell Biol.
23:6139–6149. 2003.PubMed/NCBI View Article : Google Scholar
|
|
41
|
He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang
J and Wu X: Ovarian cancer cell-secreted exosomal miR-205 promotes
metastasis by inducing angiogenesis. Theranostics. 9:8206–8220.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hong SJ, Dawson TM and Dawson VL: Nuclear
and mitochondrial conversations in cell death: PARP-1 and AIF
signaling. Trends Pharmacol Sci. 25:259–264. 2004.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Porter AG and Janicke RU: Emerging roles
of Caspase-3 in. Cell Death Differ. 6:99–104. 2015.
|
|
44
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: miR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Liu J, Tu F, Yao W, Li X, Xie Z, Liu H, Li
Q and Pan Z: Conserved miR-26b enhances ovarian granulosa cell
apoptosis through HAS2-HA-CD44-Caspase-3 pathway by targeting HAS2.
Sci Rep. 6(21197)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Masciullo V, Baldassarre G, Pentimalli F,
Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G,
Giancotti V, Viglietto G, et al: HMGA1 protein over-expression is a
frequent feature of epithelial ovarian carcinomas. Carcinogenesis.
24:1191–1198. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wei JJ, Wu X, Peng Y, Shi G, Basturk O,
Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al: Regulation
of HMGA1 expression by MicroRNA-296 affects prostate cancer growth
and invasion. Clin Cancer Res. 17:1297–1305. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen YN, Ren CC, Yang L, Nai MM, Xu YM,
Zhang F and Liu Y: MicroRNA let-7d-5p rescues ovarian cancer cell
apoptosis and restores chemosensitivity by regulating the p53
signaling pathway via HMGA1. Int J Oncol. 54:1771–1784.
2019.PubMed/NCBI View Article : Google Scholar
|
